Mycetoma is a chronic infection of skin and subcutaneous tissue. The condition was first described in the mid-1800s and was initially named Madura foot, after the region of Madura in India where the disease was first identified.

Mycetoma infection can be caused by fungi or bacteria. When caused by fungi, it is referred to as mycotic mycetoma or eumycetoma. When it is caused by bacteria, it usually involves infection by the actinomycetes group; such cases are called actinomycotic mycetoma or actinomycetoma.[1] Involvement of the lower extremities is common, and the disease presentation, whether caused by fungi or bacteria, is quite similar.

Mycetoma infection typically results in a granulomatous inflammatory response in the deep dermis and subcutaneous tissue, which can extend to the underlying bone. Mycetoma is characterized by the formation of grains, which contain aggregates of the causative organisms that may be discharged onto the skin surface through multiple sinuses.[2] The characteristic color of the grains can assist in the identification of the specific etiologic agent.

Mycetoma due to actinomycetes should be differentiated from actinomycosis, which is an endogenous suppurative infection caused by Actinomyces israelii, other species of Actinomyces, or related bacteria, typically affecting the cervical-facial, thoracic, and pelvic sites (the latter is usually associated with the use of intrauterine devices). The branching bacteria that cause actinomycosis are non–acid-fast anaerobic or microaerophilic bacteria. These bacteria are smaller than 1 µm in diameter, smaller than eumycotic agents. Alternatively, the agents that cause actinomycetoma are always aerobic and are sometimes weakly acid-fast.

More than 20 species of fungi and bacteria can cause mycetoma. Nocardia species, especially Nocardia brasiliensis, is the most commonly implicated actinomycetes.[3]

The ratio of mycetoma cases caused by bacteria (actinomycetoma) to those caused by true fungi (eumycetoma) in Mexico was 92:8.[4]


The body parts affected most commonly in persons with mycetoma include the foot or lower leg, with infection of the dorsal aspect of the forefoot being typical. The hand is the next most common location; however, mycetoma lesions can occur anywhere on the body. Lesions on the chest and back are frequently caused by Nocardia species, whereas lesions on the head and neck are usually caused by Streptomyces somaliensis.

The causative organism enters through sites of local trauma (eg, cut on the hand, thorn or foot splinter). Contaminated soil seems to be the real culprit, even when a splinter or thorn is implicated. A neutrophilic response initially occurs, which may be followed by a granulomatous reaction. Spread occurs through skin facial planes and can involve the bone. Hematogenous or lymphatic spread is uncommon.

Human-to-human or animal-to-human transmission has not been described for eumycetoma, but nosocomial transmission of Nocardia farcinica, one of the agents of actinomycetoma in postoperative surgical site infections, has been reported.[5]


Mycetoma is endemic in Africa, from Sudan and Somalia through Mauritania and Senegal. Other endemic countries include Mexico and India. Mycetoma can also be found in natives of areas of Central and South America and the Middle or Far East between latitudes 15°S and 30°N.[6]

Eumycetoma is more common in areas where the average rainfall is scarce (ie, < 350 mm), whereas actinomycetoma tends to appear in areas with abundant rainfall (ie, >600 mm)[7] and has been described in Southeast Asia.[8]

In Sudanese hospitals, at least 300-400 patients are diagnosed with mycetoma every year.

Mycetoma is rare in the United States. Some cases are acquired during international travel, but cases acquired on US soil have also been reported.[9]

In general, traumatic inoculation of fungal elements into the skin or subcutaneous tissue by a thorn or splinter typically occur in those who walk bare-footed (eg, farmers, field workers), especially in developing countries.

Among the fungal pathogens responsible for mycetoma, Madurella mycetomatis is the most common pathogen described in Africa. Madurella grisea is the most common etiologic pathogen in South America. Pseudallescheria boydii (Scedosporium apiospermum) is the most common etiologic agent in the United States.


Mycetoma causes disfigurement but is rarely fatal in the absence of skull involvement. The lesions are painless and slowly progressive; however, secondary bacterial infection or bone expansion may cause pain. When secondary bacterial infection occurs, Staphylococcus aureus is the most common etiologic agent.[10] In advanced cases, deformities or ankylosis and their corresponding disabilities can appear. Patients who are immunocompromised or who have undergone transplantation can develop invasive infection.

View Image

Mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years.

View Image

Frontal view of mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years.


Mycetoma has no apparent racial predilection.


Mycetoma has a male-to-female ratio of 3:1 to 5:1


Mycetoma is most common in persons aged 20-50 years, with a mean of 34 years.


The classic clinical triad of mycetoma is tumor or soft tissue swelling, sinus tracts, and characteristic macroscopic grains. The grains typically represent aggregates of the infecting organisms. The earliest sign is often painless subcutaneous swelling. Some patients may give a history of a penetrating injury at the site of involvement.

Several years later, a painless subcutaneous nodule is observed. After some years, massive swelling of the area occurs, with induration, skin rupture, and sinus tract formation.

As the infection spreads to contiguous body parts, old sinuses close and new ones open.

Nearly 20% of patients with mycetoma experience associated pain, usually due to secondary bacterial infection or, less commonly, bone invasion.

Constitutional symptoms and signs of mycetoma are rare.

Patients may report a deep itching sensation.


Irrespective of the causal agent, the appearance of the mycetoma lesion is consistent, as follows:

In general, eumycetoma is more circumscribed and progresses slower than actinomycetoma.

Regional lymphadenopathy is unusual; when it does occur, it is due to one of the following:

Lymphatic obstruction and fibrosis can cause lymphedema and erythema.

Pulmonary mycetoma has been found to develop and progress more rapidly in individuals infected with HIV.


Mycetoma occurs most often in farmers, shepherds, Bedouins, nomads, and people living in rural areas.

Frequent exposure to penetrating wounds by thorns or splinters is a risk factor, especially in combination with contaminated soil material.

Actinomycetoma can be caused by the following:

Eumycetoma is mainly caused by P boydii (S apiospermum), Madurella mycetomatis, or M grisea.[11] Madurella has been identified in cattle dung in rural East Africa.[12]

​The color of the grains is sometimes helpful in pinpointing the exact etiologic agent. For example, the grains of M mycetomatis or M grisea ​are typically black, while those of P boydii ​and several actinomycetes are usually faint yellowish or white.

Approach Considerations

Currently, multiple diagnostic tools are used to determine the extent of infections and to identify the causative agents of mycetoma. These include various imaging, cytological, histopathological, serological, and culture techniques; phenotypic characterization; and molecular diagnostics.[13]

Imaging Studies

Bone radiography

Only 3% of patients with mycetoma have normal radiographs.[14]

Once mycetoma has invaded the bone, the following changes may be observed:

Bone involvement has been radiographically classified, as follows:


MRI helps with the differential diagnosis and the assessment of the degree of bone and soft-tissue involvement.[15] The dot-in-circle sign is an easy-to-recognize and highly specific MRI sign of mycetoma.[16, 17]

View Image

MRI coronal section of mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years. ....

View Image

MRI with coronal view of mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years....


Single or multiple thick-walled cavities with hyperreflective echoes and no acoustic enhancement are always observed with mycetoma, whereas these features are not demonstrated in nonmycetoma swellings.

In eumycetoma, the hyperreflective echoes are sharp, corresponding to the grains in the lesion.

In actinomycetoma, the hyperreflective echoes are fine and closely aggregated and commonly settle at the bottom of the cavities.

CT scanning

This modality provides a better detail of changes than conventional radiography.


Perform a deep wedge biopsy or puncture and fine-needle aspiration to obtain a grain sample. The aspirated material is processed to form cell blocks and further studied for routine tissue histopathological examination.[18] Fine-needle aspiration cytology allows differentiating actinomycetoma from eumycetoma.[19]

Histologic Findings

Grains are surrounded closely and sometimes infiltrated by neutrophils and can be easily seen on histologic sections. In biopsy samples, staining with Gram stain (actinomycetoma) or Gomori methenamine silver or periodic acid-Schiff stains (eumycetoma) could help in identifying the causal agent. For mycetomas in which causative infectious agents cannot be isolated, histology may prove beneficial by avoiding inadvertent use of combined antifungal and antimicrobial agents so that a correct therapeutic modality can be decided.[20]


Radiographic staging of bone involvement can be found in Imaging Studies.

Lab Studies


Hematoxylin-eosin staining of a biopsy sample allows for detection of mycetoma grains.

Process hematoxylin-eosin and May-Grünwald-Giemsa staining of a cytologic smear of a sample obtained via fine-needle aspiration. Mycetoma grains can be distinguished from artifacts and other organisms by the intimate relationship between the grain and neutrophils. The appearance of the grains is as follows:

The causal agent of each type of mycetoma can be visualized better with the following:

Evaluation of the characteristics of the associated granules suggests an initial differential diagnosis, as follows:


Culture the grains obtained from a deep wedge biopsy or a sample obtained via puncture and fine-needle aspiration. The primary isolation media used should be Löwenstein-Jensen for actinomycetoma or blood agar for eumycetoma.

Superficial samples of the draining sinuses are inadequate for culture because of frequent contamination with bacteria.


Serologic diagnosis is available in a few centers and can be helpful in some cases for diagnosis or follow-up care during medical treatment. Antibodies can be determined via (1) immunodiffusion, (2) counterimmunoelectrophoresis, (3) enzyme-linked immunosorbent assay, or (4) Western blot.

Medical Care

In the treatment of mycetoma, antibiotic or antifungal therapy should be attempted first and may need to be combined with surgery,[2] especially for eumycetoma lesions in the extremities.[21]

External beam radiotherapy in doses ranging from 3.5-14 Gy has been considered successful treatment in a few selected cases.[22]

Surgical Care

Surgery is recommended for localized mycetoma lesions that can be excised completely without residual disability. Surgical reduction of large lesions can improve the patient's response to medical treatment.[23] However, partial surgical resection without subsequent use of appropriate antimicrobial or antifungal agents is prone to failure.


Consultation with specialists in infectious disease or tropical medicine is advised in areas of the world where mycetoma is unfamiliar.

Medication Summary

Treatment for mycetoma is generally a combination of medical and surgical therapy. Medical therapy alone may be sufficient for actinomycetoma, but surgery is generally needed for eumycetoma. Medical therapy is often prolonged, lasting for months to years.

Actinomycetoma is a bacterial infection that can respond to antibiotics[24] if treatment is administered early in the course of the disease.[25] A combination of 2 drugs in 5-week cycles is used. If needed, the cycles can be repeated once or twice. The following agents have been used in combination: trimethoprim-sulfamethoxazole (TMP-SMZ), dapsone (diaminodiphenylsulfone), and streptomycin sulfate. Amikacin can be substituted for streptomycin but is usually kept as a second-line drug because of its cost.

The combination of amikacin with cotrimoxazole (so-called Welsh regimen) is increasingly favored by many. Adding rifampin to the Welsh regimen (Modified Welsh regimen) allows for remissions without recurrence.[26] However, a case of actinomycetoma was reported as still improving after 5 years of continued treatment with cotrimoxazole only.[27]

In one case report, a patient required salvage therapy with amikacin and imipenem for 6 months.[28] An effective and convenient regimen combining a short course of intravenous gentamicin with a 6-month oral course of cotrimoxazole and doxycycline has been described.[29, 30]

Although eumycetoma may respond partially to antifungal agents, surgical removal is usually done first.[31] The most successful treatment option for eumycetomas is itraconazole 200 mg twice daily. This triazole antifungal is considered the criterion standard for eumycetomas. The less-expensive ketoconazole is no longer favored owing to side effects and multiple drug interactions.[32] ​ Fluconazole is also discouraged because of intrinsic resistance.[33]

P boydii (S apiospermum) mycetoma should be treated primarily with voriconazole, although it may also respond to itraconazole. Other agents that cause eumycetoma may respond intermittently to itraconazole or amphotericin B.

Voriconazole is the drug of choice for invasive infections caused by agents of eumycetoma in immunocompromised patients.

Posaconazole is highly active in vitro against Madurella mycetomatis, but terbinafine is only moderately active. Since posaconazole has an excellent safety profile, it might provide an important alternative in mycetoma therapy.[34]

Madurella mycetomatis is not susceptible to the echinocandins.[35]

Doxycycline (Bio-Tab, Doryx, Doxy, Periostat, Vibramycin, Vibra-Tabs)

Clinical Context:  Drug of choice. Broad-spectrum, synthetically derived bacteriostatic antibiotic in the tetracycline class. Almost completely absorbed, concentrates in bile, and is excreted in urine and feces as a biologically active metabolite in high concentrations. Inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. May block dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest.

Trimethoprim-sulfamethoxazole (Bactrim DS, Septra)

Clinical Context:  DOC; inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. Should be used continuously in combination with another antimicrobial for 5 wk. Cycle may be repeated prn.

Amikacin (Amikin)

Clinical Context:  Irreversibly binds to 30S subunit of bacterial ribosomes, blocks recognition step in protein synthesis, and causes growth inhibition.

Should be given continuously for 3 wk. Although somewhat expensive, it usually is active against the bacteria causing actinomycetoma. Use the patient's IBW for dosage calculation.

Dapsone (Avlosulfon)

Clinical Context:  Bactericidal and bacteriostatic against mycobacteria. Mechanism of action is similar to sulfonamides where competitive antagonists of PABA prevent formation of folic acid, inhibiting bacterial growth. Lowest-cost regimen. Change to TMP-SMZ if no response occurs after 1 mo.

Rifampin (Rimactane, Rifadin)

Clinical Context:  For use in combination with at least 1 other agent. Inhibits DNA-dependent bacterial but not mammalian RNA polymerase. Cross-resistance may occur.

Imipenem and cilastatin (Primaxin)

Clinical Context:  For treatment of multiple-organism infections in which other agents do not have wide spectrum coverage or are contraindicated due to potential for toxicity.

Gentamicin (Garamycin)

Clinical Context:  Aminoglycoside antibiotic for gram-negative coverage bacteria, including Pseudomonas species. Synergistic with beta-lactamase against enterococci. Interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits. Dosing regimens are numerous and are adjusted based on CrCl and changes in volume of distribution, as well as body space into which agent needs to distribute. Gentamicin may be given IV/IM. Each regimen must be followed by at least trough level drawn on third or fourth dose, 0.5 h before dosing; may draw peak level 0.5 h after 30-min infusion.

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of a clinical setting suggestive of actinomycetoma.

Ketoconazole (Nizoral)

Clinical Context:  Fungistatic activity. Imidazole broad-spectrum antifungal agent; inhibits synthesis of ergosterol, causing cellular components to leak, resulting in fungal cell death.

Itraconazole (Sporanox)

Clinical Context:  Fungistatic activity. Synthetic triazole antifungal agent that slows fungal cell growth by inhibiting cytochrome P-450–dependent synthesis of ergosterol, a vital component of fungal cell membranes.

Amphotericin B (Fungizone)

Clinical Context:  Polyene antibiotic produced by a strain of Streptomyces nodosus; can be fungistatic or fungicidal. Binds to sterols, such as ergosterol, in the fungal cell membrane, causing intracellular components to leak with subsequent fungal cell death.

Conventional formulation (complexed with deoxycholate) has a poor tolerability profile. Liposomal amphotericin B incorporates the drug into small unilamellar liposomes; this formulation retains the antifungal activity with less hypokalemia, anemia and infusion reactions, and far less nephrotoxicity than the conventional formulation.

Although the acquisition cost of liposomal amphotericin B is considerably higher than that of the conventional formulation, when adverse effects are considered, the calculated total costs of treatment for fungal infections are not clearly different.

Voriconazole (VFEND)

Clinical Context:  Used for primary treatment of invasive aspergillosis and salvage treatment of Fusarium species or S apiospermum infections. A triazole antifungal agent that inhibits fungal cytochrome P450-mediated 14 alpha-lanosterol demethylation, which is essential in fungal ergosterol biosynthesis.

Class Summary

In combination with surgical therapy, antifungal agents may help to attain partial response in cases of eumycetoma.

Further Outpatient Care

Patients with mycetoma should receive maintained medical treatment and follow-up care for several months to years.


There is currently no vaccine.

Educate patients to avoid activities that expose them to agents of mycetoma. Instruct patients to avoid carrying sticks and thorny branches that have had contact with soil, especially if contaminated with cattle dung.[12] ​ Footwear and protective clothing in at-risk populations, especially in developing countries, is also recommended.

The glycolytic enzyme fructose-bisphosphate aldolase (FBA) is expressed on the hyphae present in the mycetoma grain. FBA antibody levels were found to be significantly higher in eumycetoma patient sera when compared with healthy Sudanese controls. Therefore, FBA might be useful as candidate antigen for a future vaccine against mycetoma.[36]


Complications of mycetoma result mainly from toxicity due to prolonged administration of antimicrobial or antifungal drugs.

Disfigurement of the affected body parts may be a consequence of delayed treatment.

Amputation may result from neglected chronic infections.

Secondary bacterial infections can progress to full-blown bacteremia or septicemia, resulting in death.[2]


Mycetoma carries a good prognosis if the disease is promptly diagnosed and treated. Although mycetoma carries a low risk of mortality, amputations or ankylosis can lessen the quality of life.[37]

In late stages of mycetoma, the treatment response is limited.


Folusakin O Ayoade, MD, Clinical Fellow, Division of Infectious Diseases, LSU Health Science Center

Disclosure: Nothing to disclose.


Mohammad J Alam, MD, Assistant Professor of Medicine, Departments of Internal Medicine, Infectious Disease, and Emergency Medicine, University Health, Louisiana State University School of Medicine in Shreveport; Affiliate Staff Physician, Department of Internal Medicine (Infectious Disease), Schumpert Medical Center

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Pranatharthi Haran Chandrasekar, MBBS, MD, Professor, Chief of Infectious Disease, Department of Internal Medicine, Wayne State University School of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Basilio J Anía, MD, Associate Professor of Infectious Diseases, Universidad de Las Palmas de Gran Canaria; Consultant in Internal Medicine, Hospital Universitario Dr. Negrín, Spain

Disclosure: Nothing to disclose.

Larry I Lutwick, MD, FACP, Editor-in-Chief, ID Cases; Moderator, Program for Monitoring Emerging Diseases; Adjunct Professor of Medicine, State University of New York Downstate College of Medicine

Disclosure: Nothing to disclose.

Margarita Asenjo, MD, Associate Professor, Department of Radiology, Medical School of the University of Las Palmas De Gran Canaria, Spain

Disclosure: Nothing to disclose.

Raphael J Kiel, MD, Associate Professor of Medicine, Wayne State University School of Medicine; Associate Professor of Medicine, Oakland University William Beaumont School of Medicine; Consulting Staff, Infectious Diseases Division, William Beaumont Hospital; Consulting Staff, Infectious Diseases Division Providence Hospital

Disclosure: Nothing to disclose.


  1. van Belkum A, Fahal A, van de Sande WW. Mycetoma caused by Madurella mycetomatis: a completely neglected medico-social dilemma. Adv Exp Med Biol. 2013. 764:179-89. [View Abstract]
  2. Venkatswami S, Sankarasubramanian A, Subramanyam S. The madura foot: looking deep. Int J Low Extrem Wounds. 2012 Mar. 11(1):31-42. [View Abstract]
  3. McNeil MM, Brown JM. The medically important aerobic actinomycetes: epidemiology and microbiology. Clin Microbiol Rev. 1994 Jul. 7 (3):357-417. [View Abstract]
  4. Bonifaz A, Tirado-Sánchez A, Calderón L, Saúl A, Araiza J, Hernández M, et al. Mycetoma: experience of 482 cases in a single center in Mexico. PLoS Negl Trop Dis. 2014 Aug. 8(8):e3102. [View Abstract]
  5. Wenger PN, Brown JM, McNeil MM, Jarvis WR. Nocardia farcinica sternotomy site infections in patients following open heart surgery. J Infect Dis. 1998 Nov. 178 (5):1539-43. [View Abstract]
  6. van de Sande WW. Global burden of human mycetoma: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2013 Nov. 7(11):e2550. [View Abstract]
  7. Bakshi R, Mathur DR. Incidence and changing pattern of mycetoma in western Rajasthan. Indian J Pathol Microbiol. 2008 Jan-Mar. 51(1):154-5. [View Abstract]
  8. Rattanavong S, Vongthongchit S, Bounphamala K, Vongphakdy P, Gubler J, Mayxay M, et al. Actinomycetoma in SE Asia: the first case from Laos and a review of the literature. BMC Infect Dis. 2012 Dec 12. 12:349. [View Abstract]
  9. Rouphael NG, Talati NJ, Franco-Paredes C. A painful thorn in the foot: a case of eumycetoma. Am J Med Sci. 2007 Aug. 334(2):142-4. [View Abstract]
  10. Ahmed AO, Abugroun ES. Unexpected high prevalence of secondary bacterial infection in patients with mycetoma. J Clin Microbiol. 1998 Mar. 36 (3):850-1. [View Abstract]
  11. Ahmed AO, van Leeuwen W, Fahal A, et al. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis. 2004 Sep. 4(9):566-74. [View Abstract]
  12. de Hoog GS, Ahmed SA, Najafzadeh MJ, Sutton DA, Keisari MS, Fahal AH, et al. Phylogenetic findings suggest possible new habitat and routes of infection of human eumyctoma. PLoS Negl Trop Dis. 2013 May. 7(5):e2229. [View Abstract]
  13. van de Sande WW, Fahal AH, Goodfellow M, Mahgoub el S, Welsh O, Zijlstra EE. Merits and pitfalls of currently used diagnostic tools in mycetoma. PLoS Negl Trop Dis. 2014 Jul. 8(7):e2918. [View Abstract]
  14. Abd El-Bagi ME, Fahal AH. Mycetoma revisited. Incidence of various radiographic signs. Saudi Med J. 2009 Apr. 30(4):529-33. [View Abstract]
  15. El Shamy ME, Fahal AH, Shakir MY, Homeida MM. New MRI grading system for the diagnosis and management of mycetoma. Trans R Soc Trop Med Hyg. 2012 Dec. 106(12):738-42. [View Abstract]
  16. Kumar J, Kumar A, Sethy P, et al. The dot-in-circle sign of mycetoma on MRI. Diagn Interv Radiol. 2007 Dec. 13(4):193-5. [View Abstract]
  17. Jain V, Makwana GE, Bahri N, Mathur MK. The "dot in circle" sign on MRI in maduramycosis: a characteristic finding. J Clin Imaging Sci. 2012. 2:66. [View Abstract]
  18. Yousif BM, Fahal AH, Shakir MY. A new technique for the diagnosis of mycetoma using fixed blocks of aspirated material. Trans R Soc Trop Med Hyg. 2010 Jan. 104(1):6-9. [View Abstract]
  19. Hemalata M, Prasad S, Venkatesh K, Niveditha SR, Kumar SA. Cytological diagnosis of actinomycosis and eumycetoma: a report of two cases. Diagn Cytopathol. 2010 Dec. 38(12):918-20. [View Abstract]
  20. Chufal SS, Thapliyal NC, Gupta MK. An approach to histology-based diagnosis and treatment of Madura foot. J Infect Dev Ctries. 2012 Sep 17. 6(9):684-8. [View Abstract]
  21. Ahmed AA, van de Sande WW, Fahal A, et al. Management of mycetoma: major challenge in tropical mycoses with limited international recognition. Curr Opin Infect Dis. 2007 Apr. 20(2):146-51. [View Abstract]
  22. Falkson C, Sur R, Pacella J. External beam radiotherapy: a treatment option for massive haemoptysis caused by mycetoma. Clin Oncol (R Coll Radiol). 2002 Jun. 14(3):233-5. [View Abstract]
  23. Maina AM, Macharia JT. Alleviating a Nomad's Anguish: Successful Treatment of a Case of Leg Mycetoma-A Case Report. Case Rep Orthop. 2012. 2012:753174. [View Abstract]
  24. Welsh O, Vera-Cabrera L, Welsh E, Salinas MC. Actinomycetoma and advances in its treatment. Clin Dermatol. 2012 Jul. 30(4):372-81. [View Abstract]
  25. Agarwal US, Besarwal RK, Gupta R, Agarwal P. Treatment of actinomycetoma foot - our experience with ten patients. J Eur Acad Dermatol Venereol. 2012 Nov 26. [View Abstract]
  26. Damle DK, Mahajan PM, Pradhan SN, Belgaumkar VA, Gosavi AP, Tolat SN, et al. Modified Welsh regimen: a promising therapy for actinomycetoma. J Drugs Dermatol. 2008 Sep. 7(9):853-6. [View Abstract]
  27. Viguier M, Lafaurie M. Images in clinical medicine. Actinomycetoma. N Engl J Med. 2015 Jan 15. 372(3):264. [View Abstract]
  28. Baril L, Boiron P, Manceron V, et al. Refractory craniofacial actinomycetoma due to Streptomyces somaliensis that required salvage therapy with amikacin and imipenem. Clin Infect Dis. 1999 Aug. 29(2):460-1. [View Abstract]
  29. Ramam M, Bhat R, Garg T, et al. A modified two-step treatment for actinomycetoma. Indian J Dermatol Venereol Leprol. 2007 Jul-Aug. 73(4):235-9. [View Abstract]
  30. Palit A, Ragunatha S, Inamadar AC. Actinomycetoma: dramatic response to modified two-step regimen. Int J Dermatol. 2011 Apr. 50(4):446-9. [View Abstract]
  31. Estrada R, Chávez-López G, Estrada-Chávez G, López-Martínez R, Welsh O. Eumycetoma. Clin Dermatol. 2012 Jul. 30(4):389-96. [View Abstract]
  32. Nenoff P, van de Sande WW, Fahal AH, Reinel D, Schöfer H. Eumycetoma and actinomycetoma - an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy. J Eur Acad Dermatol Venereol. 2015 Feb 27. [View Abstract]
  33. Salkin IF, McGinnis MR, Dykstra MJ, Rinaldi MG. Scedosporium inflatum, an emerging pathogen. J Clin Microbiol. 1988 Mar. 26 (3):498-503. [View Abstract]
  34. van Belkum A, Fahal AH, van de Sande WW. In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine. Antimicrob Agents Chemother. 2011 Apr. 55(4):1771-3. [View Abstract]
  35. van de Sande WW, Fahal AH, Bakker-Woudenberg IA, van Belkum A. Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. Antimicrob Agents Chemother. 2010 Jun. 54(6):2738-40. [View Abstract]
  36. de Klerk N, de Vogel C, Fahal A, van Belkum A, van de Sande WW. Fructose-bisphosphate aldolase and pyruvate kinase, two novel immunogens in Madurella mycetomatis. Med Mycol. 2011 Jul 5. [View Abstract]
  37. Zein HA, Fahal AH, Mahgoub el S, El Hassan TA, Abdel-Rahman ME. Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan. Trans R Soc Trop Med Hyg. 2012 Nov. 106(11):639-44. [View Abstract]
  38. Abd El Bagi ME. New radiographic classification of bone involvement in pedal mycetoma. AJR Am J Roentgenol. 2003 Mar. 180(3):665-8. [View Abstract]
  39. Akhtar MA, Latief PA. Actinomycetoma pedis. Postgrad Med J. 1999 Nov. 75(889):671. [View Abstract]
  40. Bapat KC, Pandit AA. Actinomycotic mycetoma. Report of a case with diagnosis by fine needle aspiration. Acta Cytol. 1991 Nov-Dec. 35(6):770-2. [View Abstract]
  41. Boiron P, Locci R, Goodfellow M, et al. Nocardia, nocardiosis and mycetoma. Med Mycol. 1998. 36 Suppl 1:26-37. [View Abstract]
  42. Bouza E, Munoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect. 2004 Mar. 10 Suppl 1:76-85. [View Abstract]
  43. Campagnaro EL, Woodside KJ, Early MG, et al. Disseminated Pseudallescheria boydii (Scedosporium apiospermum) infection in a renal transplant patient. Transpl Infect Dis. 2002 Dec. 4(4):207-11. [View Abstract]
  44. Chaveiro MA, Vieira R, Cardoso J, et al. Cutaneous infection due to Scedosporium apiospermum in an immunosuppressed patient. J Eur Acad Dermatol Venereol. 2003 Jan. 17(1):47-9. [View Abstract]
  45. Chávez G, Estrada R, Bonifaz A. Perianal actinomycetoma experience of 20 cases. Int J Dermatol. 2002 Aug. 41(8):491-3. [View Abstract]
  46. Coukell AJ, Brogden RN. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs. 1998 Apr. 55(4):585-612. [View Abstract]
  47. Develoux M, Dieng MT, Kane A, et al. [Management of mycetoma in West-Africa]. Bull Soc Pathol Exot. 2003 Jan. 96(5):376-82. [View Abstract]
  48. Dieng MT, Sy MH, Diop BM, et al. [Mycetoma: 130 cases]. Ann Dermatol Venereol. 2003 Jan. 130(1 Pt 1):16-9. [View Abstract]
  49. EL Hag IA, Fahal AH, Gasim ET. Fine needle aspiration cytology of mycetoma. Acta Cytol. 1996 May-Jun. 40(3):461-4. [View Abstract]
  50. Fahal AH. Mycetoma: a thorn in the flesh. Trans R Soc Trop Med Hyg. 2004 Jan. 98(1):3-11. [View Abstract]
  51. Fahal AH, Hassan MA. Mycetoma. Br J Surg. 1992 Nov. 79(11):1138-41. [View Abstract]
  52. Fahal AH, Rahman IA, El-Hassan AM, Rahman ME, Zijlstra EE. The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg. 2011 Mar. 105(3):127-32. [View Abstract]
  53. Fahal AH, Sheik HE, Homeida MM, et al. Ultrasonographic imaging of mycetoma. Br J Surg. 1997 Aug. 84(8):1120-2. [View Abstract]
  54. Fletcher CL, Moore MK, Hay RJ. Eumycetoma due to Madurella mycetomatis acquired in Jamaica. Br J Dermatol. 2001 Dec. 145(6):1018-21. [View Abstract]
  55. Greenberg AK, Knapp J, Rom WN, et al. Clinical presentation of pulmonary mycetoma in HIV-infected patients. Chest. 2002 Sep. 122(3):886-92. [View Abstract]
  56. Hay RJ. Fungal infections. Cook GC, ed. Manson's Tropical Diseases. 20th ed. London, UK: WB Saunders; 1996. 1047-74.
  57. Hay RJ, Moore M. Mycology. Champion RH, Wilkinson DS, Ebling FJG, Breathnach SM, eds. Rook/Wilkinson/Ebling Textbook of Dermatology. 6th ed. Oxford, UK: Blackwell Science; 1998. Vol 2: 1277-376.
  58. Khatri ML, Al-Halali HM, Fouad Khalid M, et al. Mycetoma in Yemen: clinicoepidemiologic and histopathologic study. Int J Dermatol. 2002 Sep. 41(9):586-93. [View Abstract]
  59. Lichon V, Khachemoune A. Mycetoma : a review. Am J Clin Dermatol. 2006. 7(5):315-21. [View Abstract]
  60. Mahgoub ES. Medical management of mycetoma. Bull World Health Organ. 1976. 54(3):303-10. [View Abstract]
  61. Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health. 2002 Sep. 7(9):788-92. [View Abstract]
  62. Mellinghoff IK, Winston DJ, Mukwaya G, et al. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis. 2002 Jun 15. 34(12):1648-50. [View Abstract]
  63. Mendez-Tovar LJ, Mondragon-Gonzalez R, Manzano-Gayosso P, et al. [Immunoglobulins in patients with Nocardia brasiliensis actinomycetoma]. Rev Argent Microbiol. 2004 Oct-Dec. 36(4):174-8. [View Abstract]
  64. O'Bryan TA. Pseudallescheriasis in the 21st century. Expert Rev Anti Infect Ther. 2005 Oct. 3(5):765-73. [View Abstract]
  65. Poncio Mendes R, Negroni R, Bonifaz A, et al. New aspects of some endemic mycoses. Med Mycol. 2000. 38 Suppl 1:237-41. [View Abstract]
  66. Queiroz-Telles F, McGinnis MR, Salkin I, et al. Subcutaneous mycoses. Infect Dis Clin North Am. 2003 Mar. 17(1):59-85, viii. [View Abstract]
  67. Ramam M, Garg T, D'Souza P, et al. A two-step schedule for the treatment of actinomycotic mycetomas. Acta Derm Venereol. 2000 Sep-Oct. 80(5):378-80. [View Abstract]
  68. Saag MS. Mycetoma. Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 21st ed. Philadelphia, Pa: WB Saunders; 2000. 1885-7.
  69. Saarinen KA, Lestringant GG, Czechowski J, et al. Cutaneous nocardiosis of the chest wall and pleura--10-year consequences of a hand actinomycetoma. Dermatology. 2001. 202(2):131-3. [View Abstract]
  70. Sharma N, Mendiratta V, Sharma RC, et al. Pulse therapy with amikacin and dapsone for the treatment of actinomycotic foot: a case report. J Dermatol. 2003 Oct. 30(10):742-7. [View Abstract]

Mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years.

Frontal view of mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years.

MRI coronal section of mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years. On this T1-potentiated image, a large heterogenous mass surrounds the cranium. Bone invasion can be observed only in the area of the zygomatic fossa.

MRI with coronal view of mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years. The mycetoma mass invades the left parapharyngeal space and almost reaches the lumen of the pharynx.

Mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years.

Frontal view of mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years.

MRI coronal section of mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years. On this T1-potentiated image, a large heterogenous mass surrounds the cranium. Bone invasion can be observed only in the area of the zygomatic fossa.

MRI with coronal view of mycetoma in a 47-year-old shepherd from Mauritania who had a painless progressive swelling of the face for more than 20 years. The mycetoma mass invades the left parapharyngeal space and almost reaches the lumen of the pharynx.